The 503A vs. 503B pharmacy question comes down to how a compounded medication is made and who it is made for. A 503A pharmacy compounds medications based on valid prescriptions for individual patients. A 503B outsourcing facility registers with the FDA, must follow current good manufacturing practice (CGMP) requirements, and can compound at a larger scale, including for office use without a patient-specific prescription.
For telehealth operators, the difference is practical, not academic. Many direct-to-consumer programs rely on compounded products, and the pharmacy behind them affects oversight, consistency, supply, and how orders move from prescription to patient. If you are mapping out pharmacy fulfillment for telehealth or trying to understand what happens in prescription fulfillment after a provider signs off, knowing which pharmacy type you are working with is part of the foundation.
This guide explains what compounding is, how 503A and 503B pharmacies differ, when each makes sense for a telehealth brand, and what to ask before choosing a compounding partner.
What Is Drug Compounding?
The U.S. Food and Drug Administration describes compounding as "a practice in which a licensed pharmacist, a licensed physician or, in the case of an outsourcing facility, a person under the supervision of a licensed pharmacist, combines, mixes or alters ingredients of a drug to create a medication tailored to the needs of an individual patient."
Compounding can serve real needs. A patient may need a different dosage strength, a different form, or a formulation without an ingredient they cannot tolerate.
One point matters for every telehealth brand: according to the FDA, "compounded drugs are not FDA approved, which means the agency does not review their safety, effectiveness, or quality before they are marketed." That shapes how compounded products can be described in marketing, intake flows, and patient communication.
The two main federal pathways for compounding are named after sections of the Federal Food, Drug, and Cosmetic Act (FD&C Act): Section 503A and Section 503B.
What Is a 503A Pharmacy?
A 503A pharmacy is a traditional compounding pharmacy. It compounds medications in response to prescriptions for specific, identified patients.
The FDA's overview of compounding laws and policies explains that Section 503A describes the conditions under which compounded drugs are exempt from three FD&C Act requirements:
- FDA approval before marketing
- CGMP requirements
- Labeling with adequate directions for use
To qualify for those exemptions, the drug must meet several conditions. One of the most important is that the drug "must be compounded based on the receipt of valid patient-specific prescriptions."
In practice, that means a 503A pharmacy is built around the individual patient. A provider prescribes a specific person, and the pharmacy compounds that medication for that person. Like other pharmacies, 503A compounding pharmacies operate under state pharmacy licensing, and a telehealth brand needs pharmacy coverage that matches the states where its patients are located.
What Is a 503B Outsourcing Facility?
A 503B outsourcing facility is a newer category created by the Drug Quality and Security Act, enacted on November 27, 2013. Registration as an outsourcing facility is voluntary, but registered facilities take on different obligations.
According to the FDA's information for outsourcing facilities, an outsourcing facility:
- Is engaged in compounding sterile drugs and has registered with the FDA
- Can qualify for exemptions from FDA approval requirements, but not from CGMP requirements
- Is inspected by the FDA on a risk-based schedule
- Must report adverse events
- Must give the FDA a list of the drugs it compounded during the previous six months
The FDA also notes that outsourcing facilities "may distribute compounded drugs either pursuant to a patient-specific prescription or in response to an order from a health care provider, such as a hospital, that is not for an identified individual patient (e.g., for office stock)."
That is the key operational difference. A 503B facility can produce compounded medications in larger batches under manufacturing-level quality standards, rather than one prescription at a time.
503A vs. 503B: Side-by-Side Comparison
| 503A pharmacy | 503B outsourcing facility |
|---|
| Federal section | Section 503A of the FD&C Act | Section 503B of the FD&C Act |
| How it started | Long-standing pharmacy compounding pathway | Drug Quality and Security Act, November 27, 2013 |
| Prescriptions | Compounds based on valid patient-specific prescriptions | Can compound with a patient-specific prescription or for provider orders such as office stock |
| CGMP | Exempt when 503A conditions are met | Must meet CGMP requirements |
| FDA registration | Not registered as an outsourcing facility | Registers with the FDA as an outsourcing facility |
| FDA inspection | Not on the outsourcing facility inspection schedule | Inspected by the FDA on a risk-based schedule |
| Reporting to FDA | No outsourcing facility reporting | Reports adverse events and lists of compounded drugs every six months |
| Typical scale | One prescription, one patient | Larger batches |
| Common fit in telehealth | Personalized formulations and patient-specific dosing | Products where volume and consistency matter |
Neither type is better in every situation. They are built for different jobs.
Which One Does a Telehealth Brand Need?
The right pharmacy type depends on the products in your program, how much customization they need, and how much volume you expect.
When a 503A Pharmacy Makes Sense
A 503A pharmacy is often the better fit when:
- Each patient may need a different strength, form, or combination
- Providers adjust formulations as treatment progresses
- The program depends on personalized dosing rather than one standard product
- Volume per formulation is modest
Many DTC programs in dermatology, hormone therapy, and similar categories involve personalized formulations, which is where patient-specific compounding fits naturally. If you are building a program like those described in Bask's guides to teledermatology or testosterone therapy telehealth, the pharmacy model is one of the first operational questions to settle.
When a 503B Facility Makes Sense
A 503B outsourcing facility is often the better fit when:
- The product is sterile
- Consistency across large volumes matters
- The program needs predictable supply at scale
- The brand wants the added assurance of CGMP standards and FDA inspection
Why Many Brands Use Both
Larger telehealth brands often work with both pharmacy types. A brand might use 503A pharmacies for patient-specific formulations and a 503B facility for sterile or high-volume products. The key is routing each prescription to the right pharmacy automatically, so providers and support teams do not have to manage it by hand.
How a Compounded Order Moves Through a Telehealth Platform
Whichever pharmacy type you use, the patient experience depends on how smoothly the order moves from intake to delivery. A typical flow looks like this:
- Intake. The patient completes a medical questionnaire and selects a program.
- Provider review. A licensed provider reviews the patient's information and decides whether treatment is appropriate. A prescription is not guaranteed.
- Prescription. If appropriate, the provider sends an electronic prescription that specifies the compounded formulation.
- Routing. The platform sends the prescription to the right pharmacy based on the product, the patient's state, and the pharmacy type.
- Compounding and dispensing. The pharmacy prepares the medication and runs its quality checks.
- Shipping. The order ships with tracking and temperature controls if the product needs them.
- Refills. Recurring orders are triggered on schedule, often tied to a subscription and periodic provider check-ins.
Each handoff is a place where orders can stall. Common problems include prescriptions routed to a pharmacy that cannot ship to the patient's state, missing prescription details, and refills that fall out of sync with billing. A platform that connects prescribing, routing, and pharmacy status in one system catches those issues before the patient does.
Common Mistakes When Choosing a Compounding Partner
Brands new to compounding tend to run into the same few problems:
- Choosing on price alone. A lower per-unit cost can disappear if turnaround is slow or shipping fails.
- Ignoring state coverage. A pharmacy that cannot ship to a patient's state forces manual rerouting or a canceled order.
- Treating 503A and 503B as interchangeable. They follow different rules and suit different products.
- Skipping the BAA. The pharmacy handles patient information, so the agreement matters from day one.
- Building marketing before checking compliance. Copy that implies FDA approval or guarantees a prescription can create problems with ad platforms, payment processors, and regulators.
What to Ask a Compounding Pharmacy Partner
Pharmacy relationships are hard to change once patients are on active subscriptions, so ask detailed questions before signing.
- Are you a 503A pharmacy, a 503B outsourcing facility, or do you operate both?
- Which states can you ship to, and are you licensed for each one? Coverage needs to match where your patients live.
- For 503B facilities, what is your FDA registration status and recent inspection history?
- How do you test quality and potency?
- How do you handle shipping for temperature-sensitive products?
- What is your typical turnaround from prescription to shipment?
- How are refills and recurring orders handled?
- How do prescriptions reach you? Ask about e-prescribing and how orders route from the telehealth platform.
- Will you sign a Business Associate Agreement? The pharmacy handles patient information.
- How do you support compliance for online sales? Payment processors and ad platforms often expect LegitScript certification for businesses selling prescription products online. Bask's guide to LegitScript certification explains why.
Compliance Points Telehealth Operators Should Know
Compounded medications carry specific compliance expectations. These points apply regardless of the pharmacy type you use.
Do Not Imply FDA Approval
Because compounded drugs are not FDA-approved, marketing and patient-facing copy should never suggest that they are. Describe compounded products accurately, including their compounded status.
Prescriptions Are Never Guaranteed
A licensed provider decides whether a treatment is appropriate after reviewing the patient's information. Intake flows, landing pages, and ads should make clear that a prescription is not guaranteed.
Avoid Outcome Claims
Avoid promises about results, timelines, or effectiveness. Focus on what the program offers, how care works, and who reviews the patient's information.
Expect the Rules to Change
Compounding policies can shift, especially for products tied to drug shortages. Brands should review their programs regularly and get regulatory or legal guidance when rules change.
This section is general information, not legal advice. Telehealth operators should work with qualified healthcare counsel on their specific programs.
How Bask Health Handles Compounding
Bask Health connects telehealth brands to compounding infrastructure within the same platform that runs their storefront, intake, prescribing, and payments.
According to the Bask compounding page:
- Bask works with 503A pharmacies that specialize in custom-compounded medications under Section 503A
- Bask works with 503B pharmacies that follow cGMP standards to produce sterile medications at scale
- Brands can offer custom formulations, custom packaging, and personalized medications
- Orders ship to the 48 contiguous states
- More than 3.5 million orders have been fulfilled through Bask's pharmacies
Around that, Bask provides the clinical and operational layers a compounding program depends on:
- Integrated doctor networks included on every plan, with a choice of networks
- EMR and e-prescribing, so prescriptions move from provider review to the pharmacy inside one workflow
- Pharmacy fulfillment for routing, shipping updates, and refills
- Support for prescription products, OTC products, and medical devices, plus customizable treatment pathways
- HIPAA and LegitScript compliance, SOC 2 Type II controls, MFA, and audit logging
More than 250 U.S. telehealth companies run on Bask. Brands that would otherwise negotiate with pharmacies one by one can launch with compounding already connected. Compare Bask plans or talk to the Bask team to plan your pharmacy setup.
FAQs
What is the difference between a 503A and 503B pharmacy?
A 503A pharmacy compounds medications based on valid patient-specific prescriptions and is exempt from CGMP requirements when it meets Section 503A conditions. A 503B outsourcing facility registers with the FDA, must meet CGMP requirements, is inspected by the FDA on a risk-based schedule, and can compound for office stock without a patient-specific prescription.
Are compounded medications FDA approved?
No. The FDA states that compounded drugs are not FDA-approved, which means the agency does not review their safety, effectiveness, or quality before they are marketed. Telehealth brands should describe compounded products accurately in all patient-facing materials.
Does a 503B pharmacy need a prescription?
Not always. According to the FDA, outsourcing facilities may distribute compounded drugs either under a patient-specific prescription or in response to an order from a health care provider, such as a hospital, that is not for an identified individual patient.
Can a telehealth company work with both 503A and 503B pharmacies?
Yes. Many telehealth brands use 503A pharmacies for patient-specific formulations and 503B facilities for sterile or high-volume products. The platform needs to route each prescription to the right pharmacy.
How can I check whether a pharmacy is a 503B outsourcing facility?
Ask the pharmacy for its FDA outsourcing facility registration and recent inspection history, and check it against the information the FDA publishes for outsourcing facilities. A legitimate 503B facility should be able to provide this without hesitation.
Conclusion
The 503A vs. 503B pharmacy choice is a choice between two models. 503A pharmacies compound one prescription at a time for individual patients. 503B outsourcing facilities register with the FDA, follow CGMP, and produce at scale.
For a telehealth brand, the right answer depends on the products you offer, how personalized they are, and how much volume you expect. Many brands end up using both. What matters most is knowing which model each product depends on, choosing partners carefully, and describing compounded medications accurately to patients.
References
- U.S. Food and Drug Administration. (n.d.). Human drug compounding. https://www.fda.gov/drugs/guidance-compliance-regulatory-information/human-drug-compounding
- U.S. Food and Drug Administration. (n.d.). Compounding laws and policies. https://www.fda.gov/drugs/human-drug-compounding/compounding-laws-and-policies
- U.S. Food and Drug Administration. (n.d.). Information for outsourcing facilities. https://www.fda.gov/drugs/human-drug-compounding/information-outsourcing-facilities
